ArticleAddiction & health2024
Spectroscopic Screening of Dexamethasone and Cyproheptadine Adulteration in Weight Gaining Products Marketed in Aden, Yemen.
Article in Addiction & health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In vitro development and evaluation of chitosan-cellulose nanocrystal microspheres for controlled dexamethasone delivery in rheumatoid arthritis.Rheumatology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Weight-gaining (WG) products are either medicine or herbal products that have been used intensively by the young and adolescents in Yemen. These products may contain undeclared potentially toxic ingredients that can lead to several health problems and diseases on long-term usage. This study was intended to evaluate the presence of some undeclared pharmaceuticals, dexamethasone (DX) and cyproheptadine (CPR), in WG products in Aden, Yemen. Methods: The detection of DX & CPR in WG products was evaluated using UV& Fourier transform infrared (FT-IR) spectroscopy. Also, phytochemical analysis was carried out for herbal products. Findings: The study indicated the presence of CPR in Tab-II, honey mixture, and capsules in the range between 0.10%-102.6%. A lower percentage was detected in the honey mixture and a higher percentage in Tab-2. DX was only detected in Tab-I (102.87%). Conclusion: It can be concluded that WG products may contain undeclared amounts of DX and CPR. Stricter regulations must be implemented for the usage and distribution of these products to avoid potential long-term adverse consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.